273 related articles for article (PubMed ID: 35913858)
21. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of Dmax and %ΔSUVmax of
Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
[TBL] [Abstract][Full Text] [Related]
23. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
24. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
Ferrari C; Niccoli Asabella A; Merenda N; Altini C; Fanelli M; Muggeo P; De Leonardis F; Perillo T; Santoro N; Rubini G
Medicine (Baltimore); 2017 Feb; 96(5):e5973. PubMed ID: 28151888
[TBL] [Abstract][Full Text] [Related]
25. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of baseline and interim [
Yadgarov MY; Dunaykin MM; Shestopalov GI; Kailash C; Kireeva ED; Myakova NV; Likar YN
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1955-1964. PubMed ID: 38351389
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of Baseline Tumor Burden and Tumor Dissemination Extracted From 18 F-FDG PET/CT in a Cohort of Adult Patients With Early or Advanced Hodgkin Lymphoma.
Mouheb M; Pierre-Jean M; Devillers A; Fermé C; Benchalal M; Manson G; Le Jeune F; Houot R; Palard-Novello X
Clin Nucl Med; 2024 Jan; 49(1):e1-e5. PubMed ID: 38015041
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.
Le Roux PY; Gastinne T; Le Gouill S; Nowak E; Bodet-Milin C; Querellou S; Mahe B; Dubruille V; Blin N; Salaun PY; Bodere-Kraeber F
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1064-71. PubMed ID: 21308370
[TBL] [Abstract][Full Text] [Related]
29. The Utility of PET/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD.
Ingley KM; Nadel HR; Potts JE; Wilson DC; Eftekhari A; Deyell RJ
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e87-e93. PubMed ID: 31259825
[TBL] [Abstract][Full Text] [Related]
30. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
Straus DJ; Jung SH; Pitcher B; Kostakoglu L; Grecula JC; Hsi ED; Schöder H; Popplewell LL; Chang JE; Moskowitz CH; Wagner-Johnston N; Leonard JP; Friedberg JW; Kahl BS; Cheson BD; Bartlett NL
Blood; 2018 Sep; 132(10):1013-1021. PubMed ID: 30049811
[TBL] [Abstract][Full Text] [Related]
31. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
32. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.
Biggi A; Gallamini A; Chauvie S; Hutchings M; Kostakoglu L; Gregianin M; Meignan M; Malkowski B; Hofman MS; Barrington SF
J Nucl Med; 2013 May; 54(5):683-90. PubMed ID: 23516309
[TBL] [Abstract][Full Text] [Related]
33. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
[TBL] [Abstract][Full Text] [Related]
34. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.
Cashen AF; Dehdashti F; Luo J; Homb A; Siegel BA; Bartlett NL
J Nucl Med; 2011 Mar; 52(3):386-92. PubMed ID: 21321279
[TBL] [Abstract][Full Text] [Related]
35. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Evens AM; Kostakoglu L
Blood; 2014 Nov; 124(23):3356-64. PubMed ID: 25428223
[TBL] [Abstract][Full Text] [Related]
36. Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma.
Santos FM; Marin JFG; Lima MS; Silva-Junior WF; Alves LBO; Moreira FR; Velasques RD; Atanazio MJ; Maia ACA; Buchpiguel CA; Buccheri V; Rocha V
Ann Hematol; 2024 Jan; 103(1):175-183. PubMed ID: 37796339
[TBL] [Abstract][Full Text] [Related]
37. Prognostic analysis of interim
Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
[TBL] [Abstract][Full Text] [Related]
38. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Evens AM; Kostakoglu L
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):135-43. PubMed ID: 25696846
[TBL] [Abstract][Full Text] [Related]
39. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
[TBL] [Abstract][Full Text] [Related]
40. Factors affecting intrapatient liver and mediastinal blood pool ¹⁸F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma.
Chiaravalloti A; Danieli R; Abbatiello P; Di Pietro B; Travascio L; Cantonetti M; Guazzaroni M; Orlacchio A; Simonetti G; Schillaci O
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1123-32. PubMed ID: 24562647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
